An interventional study of Patient Centered Clinical Decision Support (PC-CDS) in Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome and Genetic Variation, sponsored by HealthPartners Institute. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by HealthPartners Institute · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Hereditary Breast and Ovarian Cancer Syndrome · United States.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, this one is the 2nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 with no phase, and was the 34th registered.
62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.
Browse Hereditary Breast and Ovarian Cancer Syndrome studies →7 of the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 35+ · Women only
Georgetown University · Sites in United States
Ages 18–74 · Women only
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
University of Kansas Medical Center · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,488 is above the median of 150 across 43 interventional studies indexed under Hereditary Breast and Ovarian Cancer Syndrome.
Median enrollment 157 across the 23 interventional studies, 440 across the 12 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 35 have an industry lead sponsor. The 10 most frequent:
HealthPartners Institute is the lead sponsor of 168 studies on the registry; 21 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
HealthPartners Institute has 1 study filed under Hereditary Breast and Ovarian Cancer Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02302742University of Kansas Medical CenterTriple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry | 2026-12 |
| NCT06892275Georgetown UniversityThe FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI | 2027-06 |
| NCT05677048M.D. Anderson Cancer CenterFeasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to address care gaps for participants at high risk of breast and ovarian cancer (HBOC), or Lynch syndrome (LS) because of testing positive for specific genetic variants. A patient-centered clinical decision support (PC-CDS) tool will help identify participants with genetic variations and display recommendations for referrals and testing to the clinician and participant at a primary care visit. The main question the study aims to answer is:
- Does clinical decision support for participants with hereditary cancer syndromes improve the use of evidence-based cancer prevention care.
Participants being seen in the PC-CDS group are compared to participants being seen in usual care (UC) to see if they are up to date on guideline-based cancer prevention care and to see if participants in the PC-CDS group report more shared decision making and higher rates of self-management of their genetic cancer risks.
Participants will be asked to answer survey questions.
Among the estimated one million Americans who have screened positive for specific genetic variants related to Hereditary Breast and Ovarian Cancer Syndrome (HBOC) or Lynch Syndrome (LS), less than half are up to date on evidence-based cancer prevention measures that may increase early detection of syndrome-related cancers or prevent these cancers altogether. Most patients newly diagnosed with hereditary cancer syndromes receive extensive initial care from genetic counselors or oncology teams but for many patients without a cancer diagnosis at the time of syndrome identification, access to regular follow-up care from oncologists and genetic counselors is limited. Pilot data show that the most frequent source of care for patients with HBOC or LS is the primary care setting, but many primary care clinicians (PCC) are unfamiliar with rapidly evolving cancer prevention guidelines for patients with HBOC or LS. Although PCCs are ideally positioned to make timely referrals to subspecialists for indicated cancer prevention care and procedures, access to evidence-based clinical decision support to optimize care for patients with these hereditary cancer syndromes does not exist.
PCCs provide care to over 80% of patients with HBOC or LS each year and are trained in shared decision making and coordination of care. However, the majority of PCCs are unaware of current recommendations for HBOC and LS and thus often fail to arrange appropriate referrals or procedures, including referrals to genetic counselors. The intervention targets these System and PCC-related barriers such as lack of awareness of the genetic condition, lack of knowledge of current evidence-based variant- specific care recommendations, and lack of timely referral for cancer prevention tests or procedures recommended for these high-risk patients. Both average-risk and high-risk patients are more likely to receive recommended cancer screening procedures when advised by their PCC.
The PC-CDS intervention also targets patient-related barriers to care, such as lack of awareness that certain tests or procedures are due, and lack of awareness of the benefits of certain interventions, tests, or procedures, and facilitates timely referral for access to subspecialists who can provide recommended services and procedures. Screening for CDC Tier 1 genetic conditions is rapidly increasing, but many of those who screen positive for HBOC or LS are not well-informed of evolving evidence-based care options. Current oncology teams are staffed primarily to deal with active management of cancer and have limited capacity to provide long-term care to large numbers of patients without diagnosed cancers. An estimated 33-50% of those diagnosed with these hereditary cancer syndromes do not complete a visit with a genetic counselor, with well-documented disparities in care for individuals with low income, low education, residence in inner city or rural areas, or membership in underserved racial/ethnic groups. Many patients with HBOC or LS are unaware of their risks, and the substantial health benefits obtainable by early detection and intervention; or lack the ability to coordinate their care across multiple subspecialists and care team members.
The PC- CDS provides each patient an updated list of variant-specific recommended care options and encourages and enables patients to have informed discussions of evidence-based care options with their PCCs or other trusted physicians. PCC referrals and suggestions will both directly and indirectly (through attitudes towards genetic conditions and intentions to access care) influence patient actions to adhere to evidence-based guidelines including (i) timely referrals to subspecialists (such as genetic counselors, oncologists, gastroenterologists, gynecologists, urologists, dermatologists, or surgeons) and (ii) engagement in recommended cancer prevention protocols and screening procedures.
This project provides evidence-based cancer prevention care recommendations to patients with HBOC or LS and their PCCs at primary care encounters when a given patient is not up to date on NCCN-recommended cancer prevention referrals and procedures. This specific application of health informatics technology to care of patients with these and other genetic variants is novel, in part because it relies on very recent advances in health informatics, increased rates of genetic screening within healthcare systems, and an accelerating (and rapidly evolving) knowledge base that supports an evidence-based set of variant-specific care recommendations. The intervention takes advantage of these recent developments and is designed to rapidly translate new genetic knowledge into evidence-based patient-specific clinical care. The variant-specific PC-CDS does not yet exist in primary care settings, and this project will provide a much-needed assessment of the impact of a PC-CDS intervention on cancer prevention care, shared decision making, and self-efficacy in managing hereditary cancer risks, as well as PCC knowledge of HBOC and LS cancer prevention care.
The web-based nature of the PC-CDS system, its prior success in improving primary care for a wide range of other chronic conditions, and its high use rates in primary care settings suggest that this approach to care improvement may be an effective strategy to increase appropriate referrals and evidence-based preventive care of adults with these hereditary cancer syndromes.
Inclusion Criteria: The patient must meet all the following inclusion criteria on date of the Index Visit:
Exclusion Criteria:
All patients and clinicians at UC clinics will continue to receive an existing EHR-linked clinical decision support for management of major uncontrolled cardiovascular risk factors and other selected chronic conditions. The existing CDS displayed at UC clinics does not include patient-specific information on recommended cancer prevention activities for those with HBOC or LS.
All patients and clinicians at PC-CDS clinics will continue to receive an existing EHR-linked clinical decision support for management of major uncontrolled cardiovascular risk factors and other selected chronic conditions plus patient-specific information on recommended cancer prevention activities for those with HBOC or LS.
Other: Patient Centered Clinical Decision Support (PC-CDS)
The intervention provides patient specific recommendations on managing cancer risk due to hereditary cancer gene variants that is integrated into an existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and all subsequent primary care encounters using the most up to date available clinical information.
Also known as: Genetics Wizard
Resolved care gaps
Proportion of patients with a care gap for a specific genetic variant (HBOC: BRCA1, BRCA2; LS: MLH1, MSH2, MSH6, PMS2, or EPCAM) that is resolved within 18 months of index date.
Time frame: 18 months after index date
Shared decision making
Patient reports of shared decision making about their genetic risk using the Shared Decision-Making Questionnaire (SDM-Q-9) with total scores ranging from 0-45.
Time frame: 12 months after index date
Self-efficacy
Patient reports of self-efficacy in managing cancer-related genetic risk using a modified version of the 12-item Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer) with scores ranging from 12-48.
Time frame: 12 months after index date
Resolved care gaps
Proportion of patients with a care gap for a specific genetic variant (HBOC: BRCA1, BRCA2; LS: MLH1, MSH2, MSH6, PMS2, or EPCAM) that is resolved within 12 months of index date.
Time frame: 12 months after index date
Plan to share: Yes — Results of the study will be presented at local, regional, and national meetings and with HPMG leaders and leaders of other health care systems in the Twin Cities area. Results will also be published in peer-reviewed journals. The PC-CDS tool is Web-based, with potential for wide dissemination beyond HPMG. If permitted under then-current law, at the conclusion of the funding period, we plan to provide a de-identified data set to NCI for retention in a qualified data repository with appropriate mechanisms in place to guide the use of these data by other qualified researchers in the future.
Supporting information: Study protocol
Started Jul 2025 (actual). Primary completion is estimated for Jun 2028, 35 months after the start.
Of 23 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31. This study's planned 35 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hereditary Breast and Ovarian Cancer Syndrome →